Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

Fernando Bazán, Erion Dobi, Bernard Royer, Elsa Curtit, Luigi Mansi, Nathalie Menneveau, M Paillard, Guillaume Meynard, C. Villanueva, Xavier Pivot,

BMC Cancer · 2019 · 18 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

BACKGROUND: Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patients with central nervous system (CNS) metastases of breast cancer. METHODS: Twenty-two patients with CNS metastases treated by MTX (3 g/m2) between April 2004 and October 2009 were enrolled. Clinical response rate, time to progression (TTP), overall survival (OS), and safety were assessed. RESULTS: In terms of brain metastases, 2 patients (9%) achieved a partial response, 10 patients (45%) had disease stabilization, and 10 patients (45%) had disease progression. In others metastatic sites, 7 patients (39%) achieved a disease stabilization, and 11 patients (61%) had disease progression. TTP and OS were 2.1 (95%CI 1.4-2.9) and 6.3 (95%CI 1.8-10) months, respectively. CONCLUSION: . Nonetheless, the favorable toxicity profile should suggest the possibility to increase the dosage and further study are planned.

References

15